Data does not support nod for BioMarin's DMD drug: FDA staff
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company
November 20, 2015 11:19 AM ESTNeedham & Company analyst Chad Messer said FDA concerns on BioMarin's drisapersen should be a positive for Sarepta Therapeutic (NASDAQ: SRPT) Eteplirse. The firm reiterated a Buy rating and price target of $55.
Messer commented, "The FDA released briefing documents for BioMarin's drisapersen this... More
Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners
November 20, 2015 10:21 AM ESTLeerink Partners analyst Joseph Schwartz weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following today's FDA briefing docs, noting they were even more harsh then expected. That said, the analyst said the jury is still out.
Schwartz commented, "FDA briefing documents for... More
BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)
November 20, 2015 9:50 AM ESTBaird analyst Brian Skorney weighed in on BioMarin Pharma (NASDAQ: BMRN) after today's Drisapersen briefing docs, calling them "ugly"
Skorney commented, "The FDA isn't even offering voting questions to the panelist and the review on risk benefit states: The benefit of drisapersen in exon... More
